


Organic & Biomolecular Chemistry

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: D. Fox, M. S. Perryman, M. Earl, S. Greatorex and G. J. Clarkson, *Org. Biomol. Chem.*, 2014, DOI:



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Synthesis of 1- and 4-substituted piperazin-2-ones via Jodic-type reactions with *N*-substituted diamines

Michael S. Perryman, Matthew W. M. Earl, Sam Greatorex, Guy J. Clarkson and David J. Fox*

Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX


DOI: 10.1039/b000000x

Enantiomerically-enriched trichloromethyl-containing alcohols, obtained by asymmetric reduction, can be transformed regioselectively into 1-substituted piperazinones by modified Jodic reactions with little or no loss of stereochemical integrity. This methodology can be easily used to synthesise important pharmaceutical compounds such as the fluorobenzyl intermediate of a known PGGTase-I inhibitor.

10 Introduction

Substituted piperazin-2-ones, and related piperazines, are important pharmacophores¹ which can be found in several medically relevant compounds, such as nonsteroidal androgen receptor antagonists,² hepatitis C virus replication inhibitors,³ DPP-4 inhibitors,⁴ elastase inhibitors,⁵ PGGTase-I inhibitors,⁶ antidepressants,^{4b, 7} HDAC inhibitors,⁸ neurokinin receptor antagonist GW597599,⁹ melanocortin receptors,^{4b, 8b, 10} CCR5 receptor antagonists,¹¹ anti-bacterials,¹² bradykinin receptor antagonists,¹³ serotonin receptor antagonists,¹⁴ GPIIb/IIIa antagonists,¹⁵ PET probes for Rho-kinases,¹⁶ and conformationally constrained peptides.¹⁷ Whilst the synthesis of enantiomerically enriched 1- and 4-substituted piperazin-2-ones have been reported in the literature it still remains a great challenge.^{1d, 5, 9, 18} To date enantiomerically-pure substituted

piperazin-2-ones can be made by the dynamic resolution of α -halo chiral esters,^{1d, 19} the kinetic resolution of *N*-heterocycles,²⁰ and manipulation of 'chiral pool' compounds such as naturally-occurring amino acids.^{1a, 5, 17g, 18a}




Scheme 1 Previously reported work.

Results

Due to the medicinal relevance of 1-substituted piperazin-2-

ones²⁵ we attempted to develop a generic method for the synthesis of this class of compounds. Boc-protection of (S)-1 lead to (S)-2 in excellent yield and without significant loss of stereochemical integrity (Scheme 2). However, deprotonation of the amide NH with sodium hydride and subsequent alkylation with benzyl bromide lead to the formation of the product (S)-3 with 45 % e.e. (a loss of 40 % e.e.).



Scheme 2 Reagents and conditions: (i) Boc₂O, NaOH, H₂O, rt, 17 h; (ii) NaH, THF, 0 °C, 90 mins, then BnBr, 0 °C to rt, 18 h.

We therefore investigated the regioselectivity and enantiospecificity of Jodic-type reactions of enantiomerically enriched trichloromethyl-substituted alcohol (R)-4 (95 % e.e.) with unsymmetrical mixed-primary-secondary 1,2- and 1,3-diamines (Table 1). Generally, as the size of the nitrogen substituent R² of the secondary amine increases the formation of 1-substituted piperazin-2-ones is favoured. With R² = methyl (entry 2) there is no preference for either the 1- or 4-substituted piperazin-2-one, giving an equal mixture of **7** and **8** in high enantiomeric excess. However, increasing the size of the amine substituent gives a much improved ratio (R² = Et, 75 : 25, entry 3), which increases further with R² = isopropyl to 95 : 5 (entry 4). We also showed that this reaction worked well with *N*-phenylethylenediamine, which gives the 1-substituted product (S)-12 in 52 % yield and 98 % e.e. (entry 5). It is possible to synthesise substituted diazepam-2-ones **13** and **14** with *N*-benzyl-1,3-propanediamine (entry 6). The formation of the 1-substituted piperazin-2-one may be favoured by the preferential attack of the less sterically encumbered primary amine opening the 2,2-dichloroepoxide.²⁶ The regioselectivity of related reactions of achiral trichloro-tertiary-alcohols also favours 1-substituted products, but with lower regioselectivity.²⁶⁻²⁷ Crystal structures of racemic samples **5**, **6** and **12** confirmed the regiochemistry of

these products (Figure 1). Some 4-substituted isomers (*S*)-**6**, (*S*)-**8** or **14** were independently synthesised by alkylation of the related *N*-unsubstituted piperazinones **1** and **12** or diazepanone **15**²⁴ in the presence of mild base without deterioration of enantiomeric excess (Table 2).

Table 1 Jocic-type reactions with unsymmetrical diamines

Entry	R	n	Ratio ^a a : b	Yield ^b		e.e. ^c		Products	
				a	b	a	b	a	b
1	CH ₂ Ph	1	93 : 7	76	6	94 ^d	98	5	6
2	CH ₃	1	50 : 50	46	41	94	96	7	8
3	CH ₂ CH ₃	1	75 : 25	72	5	96	95	9	10
4	CH(CH ₃) ₂	1	95 : 5	72	-	99	-		11
5	Ph	1	> 90 : 10	52	-	98	-		12
6	CH ₂ Ph	2	73 : 27	53	11	99	97	13	14

^a by ¹H NMR of crude product of racemic reaction; ^b isolated yield; ^c by chiral HPLC analysis; ^d by chiral HPLC analysis on *N*-Boc derivative.




Figure 1 Crystal structures of racemic **5**, **6** and **12** establishing Jocic reaction regiochemistry.


Table 2 Amine-alkylations with mild base.

Entry	R ¹	n	S.M. ^a	R ²	Yield ^c	e.e. ^e	Products
1	H	1	(<i>S</i>)- 1	CH ₃	37	95	(<i>S</i>)- 8
2	H	1	(<i>S</i>)- 1	CH ₂ Ph	58	95	(<i>S</i>)- 6
3	H	2	15 ^b	CH ₂ Ph	>95 ^d	n/a	14
4	Ph	1	(<i>S</i>)- 12	CH ₂ Ph	50	98	(<i>S</i>)- 20

^a starting material, see table 1 for e.e. ^b racemic starting material; ^c isolated yield; ^d conversion by ¹H NMR; ^e by chiral HPLC analysis.


Despite the synthesis of analogous seven-membered lactams often occurring with lower rates of ring closure than six-membered rings,²⁸ the synthesis of *N*-unsubstituted²⁴ and 4-benzyl diazepanones (table 1, entry 6) is possible. *N*-Arylation does however significantly impede ring closure in favour of intermolecular amide formation, with no 1-phenyl diazepanone being formed. A trace amount of the 4-phenyl regioisomer was however produced showing that the ring closure of the primary

amine is again relatively fast. The unexpected diamine product was independently synthesised using a *N*¹-protected arylated diamine (Scheme 4).




Scheme 4 Reagents and conditions: (i) H₂N(CH₂)₃NHPh, NaOH, BnNEt₃Cl, CH₂Cl₂, H₂O, 17 h, rt; (ii) H₂N(CH₂)₃N(Ph)CH₂Ph, NaOH, BnNEt₃Cl, CH₂Cl₂, H₂O, 17 h, rt, 18 %; (iii) 10 % Pd/C, HCO₂NH₄, MeOH, reflux, 3 h, 60 %.

A single methyl group provides a small degree of selectivity in the reaction of a phenylenediamine (**18** and **19**), and the relative reactivity of *N*-phenyl and *N*-benzyl ends of an unsymmetrical ethylene diamine is also less selective (**20** and **21**) (Scheme 5).




Scheme 5 Reagents and conditions: (i) *N*-methyl-1,2-phenylenediamine, NaOH, BnNEt₃Cl, H₂O, CH₂Cl₂, rt, 17 h; (ii) as (i) but with *N*¹-benzyl-*N*²-phenyl-1,2-ethylenediamine.

Substituted piperazin-2-ones containing an α -benzyl side chain are present in several medically relevant building blocks such as conformationally restricted peptidomimetics.^{17c, 17l, 25c, 29} Unfortunately, enantiomerically pure 1,1,1-trichloro-2-phenylpropan-2-ol, the starting material for the Jocic-type reaction, cannot be synthesised via Ru-catalysed asymmetric transfer hydrogenation.²⁴ However, 1,1,1-trichloro-3-phenylpropan-2-one can be reduced asymmetrically using the CBS catalyst^{21a} leading to a general route for the synthesis of compounds such as (*S*)-**24** containing this side chain (Scheme 6). Additionally, we wanted to demonstrate the utility of the reported method using ATH by preparing a key fluorobenzyl intermediate (*S*)-**27** in the synthesis of a PGTase-I inhibitor (Scheme 7).^{6b}




Scheme 6 Reagents and conditions: (i) (*S*)-CBS cat. (10 mol %), catecholborane, toluene-THF, -78 °C to rt, 17 hours; (ii) *N*-

benzylethylenediamine, BnNEt_3Cl , NaOH , H_2O , CH_2Cl_2 , 0°C to rt, 17 h.



Scheme 7 Reagents and conditions: (a) (R,R) -TsDPENRu(*p*-cymene) Cl (5 mol %), formic acid/triethylamine (5:2), N_2 , 28°C , 17 h; (d) *N*-4-fluorobenzylethane-1,2-diamine, BnNEt_3Cl , NaOH , H_2O , CH_2Cl_2 5°C to rt, 17 h.

It is known that Jocić / Bargellini reactions that proceed via dichloroepoxide intermediates^{21k} can also be performed in alcohols instead of chlorinated solvents.^{21g, h, 21m, 30} We found that with amine nucleophiles a high, but not perfect, level of stereochemical integrity could be obtained in the amino amide products, however yields are lower than in the biphasic reaction system (Scheme 8).



Scheme 8 Reagents and conditions: ^a NaOH (5 equiv.), MeOH , 55°C , ^b NaOMe (5 equiv.), MeOH , rt.

Conclusions

The stereospecific and regioselective synthesis of 1-substituted piperazin-2-ones, where the order of addition of the diamine to the notionally 1,2-bis-electrophilic trichloromethyl-alcohol, is controlled by the size of the amine substituent. The good levels of regiocontrol for *N*-benzyl piperazinones is particularly useful as many there are many examples of this substructure are found in compounds with potentially medicinal activity. The reactions in methanol show that this process has some potentially useful possibilities for a simpler mono-phasic system.

Acknowledgements

We wish to thank University of Warwick (studentship for MSP, URSS funding for MWME) for funding, Johnson Matthey Plc for the kind donation of catalyst 3, and Prof. Martin Wills for use of, and help with, chiral GC analysis. The Oxford Diffraction

Gemini XRD system was obtained with support from Advantage West Midlands and part funded by the European Regional Development Fund.

Experimental

General Information:

^1H and ^{13}C NMR spectra were recorded in CDCl_3 on Bruker Advance DRX 250, 300, 400 and 600 MHz spectrometers at room temperature. Chemical shifts are reported in parts per million (ppm) and referenced from CDCl_3 (δ_{H} : 7.26 ppm and δ_{C} : 77.0 ppm). Coupling constants (*J*) are rounded to the nearest 0.5 Hz. ^1H and ^{13}C assignments were established on the basis of ^1H - ^1H COSY, DEPT, HMQC and HMBC correlations. All commercially available solvents and chemicals were used without further purification.

Representative Procedure for Jocić-type Reactions with Amines: Synthesis of 1-benzyl-3-phenethylpiperazin-2-one 5 and 4-benzyl-3-phenethylpiperazin-2-one 6:

(*R*)-1,1,1-Trichloro-4-phenylbutan-2-ol (*R*)-4 (254 mg, 1 mmol, 1 equiv., 95 % e.e.) and benzyltriethylammonium chloride (4.6 mg, 0.02 mmol, 0.02 equiv.) were stirred in CH_2Cl_2 (1 mL) on ice. *N*-Benzyl-1,2-ethylenediamine (0.75 mL, 5 mmol, 5 equiv.) was added, and the mixture was stirred at 10 minutes before the dropwise addition of NaOH (10 M aq.) (0.5 mL, 5 mmol, 5 equiv.). The reaction mixture was stirred for a further 15 minutes on ice before being allowed to warm to room temperature where it was stirred for 17 hours. Distilled water (15 mL) was added and the mixture was extracted with CH_2Cl_2 (3 x 15 mL). The organic extracts were combined, dried (MgSO_4) and concentrated *in vacuo*. The residue was purified by silica column chromatography (50 % ethyl acetate in 40-60 petroleum ether to 10 % MeOH in ethyl acetate) to give (*S*)-1-benzyl-3-phenethylpiperazin-2-one (*S*)-5 as a yellow solid (224 mg, 76 %, 94 % e.e.) and (*S*)-4-benzyl-3-phenethylpiperazin-2-one (*S*)-6 as a yellow solid (18 mg, 6 %, 98 % e.e.). 1-Benzyl-3-phenethylpiperazin-2-one 5: m.p. $58-61^\circ\text{C}$; $\nu_{\text{max}}/\text{cm}^{-1}$ (neat) 3328 (br. m, NH st.), 1629 (s, C=O st.), 1227 (s, C-N st.); δ_{H} (400 MHz; CDCl_3) 7.36-7.17 (10H, m, *ArH*), 4.64 (1H, d, *J* 14.5, *NCHHPh*), 4.57 (1H, d, *J* 14.5, *NCHHPh*), 3.51 (1H, dd, *J* 8.5 and 4, *CHN*), 3.31 (1H, ddd, *J* 11.5, 8.5 and 4.5, *CHHNBN*), 3.16-3.13 (1H, m, *CHHNH*), 3.10-3.06 (1H, m, *CHHNBN*), 2.95 (1H, ddd, *J* 13.5, 10.5 and 5, *CHHNH*), 2.85-2.71 (2H, m, $\text{CH}_2\text{CH}_2\text{Ph}$), 2.37 (1H, dddd, *J* 14, 10.5, 7 and 4, *CHHCHCO*), 2.03 (1H, dddd, *J* 14, 9.5, 8.5 and 6, *CHHCHCO*); δ_{C} (100 MHz; CDCl_3) 171.2 (CO), 141.6 ($(\text{CH}_2)_2\text{ArC}_{\text{quat}}$), 136.9 ($\text{NCH}_2\text{ArC}_{\text{quat}}$), 128.6 (ArC), 128.5 (ArC), 128.4 (ArC), 128.1 (ArC), 127.4 (ArC), 125.9 (ArC), 58.7 (CHN), 50.1 (NCH_2Ph), 47.6 (CH_2NBn), 41.7 (CH_2NH), 34.1 (CH_2CHCO), 32.3 ($\text{CH}_2\text{CH}_2\text{Ph}$); HRMS (ESI) calc. for $\text{C}_{19}\text{H}_{23}\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$) 295.1805, found 295.1807; $[\alpha]_{\text{D}}^{26} = (c\ 0.24, \text{CHCl}_3): -52.2$. Enantiomeric excess determined by HPLC analysis on *N*-Boc derivative (see ESI). 4-Benzyl-3-phenethylpiperazin-2-one 6: m.p. $125-127^\circ\text{C}$; $\nu_{\text{max}}/\text{cm}^{-1}$ (neat) 3201 (br., NH st.), 1666 (s, C=O st.), 1494 (m, NH bend); δ_{H} (400 MHz; CDCl_3) 7.28-7.04 (10H, m, *ArH*), 6.73 (1H, br. s, NH), 3.89 (1H, d, *J* 13.5, *NCHHPh*), 3.33 (1H, d, *J* 13.5, *NCHHPh*), 3.24-3.21 (2H, m, CH_2NH), 3.09 (1H, t, *J* 5, *CHN*), 2.89 (1H, dt, *J* 12.5 and 5,

CHHNbN), 2.79 (1H, ddd, *J* 14, 11 and 5.5, CH₂CHHPh), 2.62 (1H, ddd, *J* 13.5, 11 and 5.5, CH₂CHHPh), 2.42 (1H, dt, *J* 12.5 and 6, CHHNbN), 2.22 (1H, ddt, *J* 14, 11 and 5, CHHCHCO), 2.04 (1H, ddt, *J* 14, 10.5 and 5, CHHCHCO); δ_{C} (100 MHz; CDCl₃) 172.4 (CO), 142.2 ((CH₂)₂ArC_{quat}), 138.1 (NCH₂ArC_{quat}), 128.8 (ArC), 128.5 (ArC), 128.4 (ArC), 128.3 (ArC), 127.3 (ArC), 125.7 (ArC), 64.1 (CHN), 58.2 (NCH₂Ph), 45.0 (CH₂NbN), 39.9 (CH₂NH), 32.0 (CH₂CHCO), 31.4 (CH₂CH₂Ph); HRMS (ESI) calc. for C₁₉H₂₃N₂O (M+H⁺) 295.1805, found 295.1815; [α]_D²⁶ = (c 0.28, CHCl₃): – 3.0. Enantiomeric excess determined by HPLC analysis (see ESI).

Notes and references

^a Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, U.K. E-mail: d.j.fox@warwick.ac.uk

[†] Electronic Supplementary Information (ESI) available: synthesis details, NMR spectra, chiral HPLC chromatograms and crystallographic details. Crystal structures have been deposited at the Cambridge Crystallographic Data Centre and assigned the deposition numbers CCDC 1022612–1022614. See DOI: 10.1039/b000000x/

1. a) C. J. Dinsmore and D. C. Beshore, *Org. Prep. Proc. Int.*, 2002, **34**, 367–404; b) D. A. Horton, G. T. Bourne and M. L. Smythe, *Chem. Rev.*, 2003, **103**, 893–930; c) C. De Risi, M. Pelà, G. P. Pollini, C. Trapella and V. Zanirato, *Tetrahedron: Asymmetry*, 2010, **21**, 255–274; d) J. I. Jang, S. Y. Kang, K. H. Kang and Y. S. Park, *Tetrahedron*, 2011, **67**, 6221–6226.
2. a) I. Kinoyama, N. Taniguchi, T. Yoden, H. Koutoku, T. Furutani, M. Kudoh and M. Okada, *Chem. Pharm. Bull.*, 2004, **52**, 1330–1333; b) I. Kinoyama, N. Taniguchi, E. Kawaminami, E. Nozawa, H. Koutoku, T. Furutani and M. Okada, *Chem. Pharm. Bull.*, 2005, **53**, 402–409.
3. a) J. B. Shotwell, S. Baskaran, P. Chong, K. L. Creech, R. M. Crosby, H. Dickson, J. Fang, D. Garrido, A. Mathis, J. Maung, D. J. Parks, J. J. Pouliot, D. J. Price, R. Rai, J. W. Seal, U. Schmitz, V. W. F. Tai, M. Thomson, M. Xie, Z. Z. Xiong and A. J. Peat, *ACS Med. Chem. Lett.*, 2012, **3**, 565–569; b) J. F. Miller, P. Y. Chong, J. B. Shotwell, J. G. Catalano, V. W. F. Tai, J. Fang, A. L. Banka, C. D. Roberts, M. Youngman, H. Zhang, Z. Xiong, A. Mathis, J. J. Pouliot, R. K. Hamatake, D. J. Price, J. W. Seal, L. L. Stroup, K. L. Creech, L. H. Carballo, D. Todd, A. Spaltenstein, S. Furst, Z. Hong and A. J. Peat, *J. Med. Chem.*, 2013, **57**, 2107–2120; c) R. Kakarla, J. Liu, D. Naduthambi, W. Chang, R. T. Mosley, D. Bao, H. M. M. Steuer, M. Keilman, S. Bansal, A. M. Lam, W. Seibel, S. Neilson, P. A. Furman and M. J. Sofia, *J. Med. Chem.*, 2014, **57**, 2136–2160.
4. a) G.-B. Liang, X. Qian, D. Feng, T. Biftu, G. Eiermann, H. He, B. Leiting, K. Lyons, A. Petrov, R. Sinha-Roy, B. Zhang, J. Wu, X. Zhang, N. A. Thornberry and A. E. Weber, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 1903–1907; b) H. J. Kim, W. Y. Kwak, J. P. Min, J. Y. Lee, T. H. Yoon, H. D. Kim, C. Y. Shin, M. K. Kim, S. H. Choi, H. S. Kim, E. K. Yang, Y. H. Cheong, Y. N. Chae, K. J. Park, J. M. Jang, S. J. Choi, M. H. Son, S. H. Kim, M. Yoo and B. J. Lee, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 3809–3812.
5. J. Seibel, D. Brown, A. Amour, S. J. Macdonald, N. J. Oldham and C. J. Schofield, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 387–389.
6. a) H. E. Huber, R. G. Robinson, A. Watkins, D. D. Nahas, M. T. Abrams, C. A. Buser, R. B. Lobell, D. Patrick, N. J. Anthony, C. J. Dinsmore, S. L. Graham, G. D. Hartman, W. C. Lumma, T. M.

- Williams and D. C. Heimbrook, *J. Biol. Chem.*, 2001, **276**, 24457–24465; b) H. Peng, D. Carrico, V. Thai, M. Blaskovich, C. Bucher, E. E. Pusateri, S. M. Sebt and A. D. Hamilton, *Org. Biomol. Chem.*, 2006, **4**, 1768–1784.
7. a) D. S. Carter, H.-Y. Cai, E. K. Lee, P. S. Iyer, M. C. Lucas, R. Roetz, R. C. Schoenfeld and R. J. Weikert, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 3941–3945; b) C. L. E. Broekkamp, D. Leysen, B. W. M. M. Peeters and R. M. Pinder, *J. Med. Chem.*, 1995, **38**, 4615–4633; c) D. V. N. S. Rao, R. Dandala, V. K. Handa, M. Sivakumaran and A. Naidu, *ARKIVOK*, 2006, **2006**, 1–9.
 8. a) D. V. Smil, S. Manku, Y. A. Chantigny, S. Leit, A. Wahhab, T. P. Yan, M. Fournel, C. Maroun, Z. Li, A.-M. Lemieux, A. Nicolescu, J. Rahil, S. Lefebvre, A. Panetta, J. M. Besterman and R. Déziel, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 688–692; b) B. Chetan, M. Bunha, M. Jagrat, B. N. Sinha, P. Saiko, G. Graser, T. Szekeres, G. Raman, P. Rajendran, D. Moorthy, A. Basu and V. Jayaprakash, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 3906–3910.
 9. a) R. Di Fabio, C. Griffante, G. Alvaro, G. Pentassuglia, D. A. Pizzi, D. Donati, T. Rossi, G. Guercio, M. Mattioli, Z. Cimarosti, C. Marchioro, S. Provera, L. Zonzini, D. Montanari, S. Melotto, P. A. Gerrard, D. G. Trist, E. Ratti and M. Corsi, *J. Med. Chem.*, 2009, **52**, 3238–3247; b) G. Guercio, S. Bacchi, M. Goodyear, A. Carangio, F. Tinazzi and S. Curti, *Org. Proc. Res. Dev.*, 2008, **12**, 1188–1194.
 10. A. Todorovic and C. Haskell-Luevano, *Peptides*, 2005, **26**, 2026–2036.
 11. X.-H. Jiang, Y.-L. Song and Y.-Q. Long, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 3675–3678.
 12. A. Khalaj, N. Adibpour, A. R. Shahverdi and M. Daneshlab, *Eur. J. Med. Chem.*, 2004, **39**, 699–705.
 13. a) Y. L. Kam, S.-J. Rhee and H.-Y. P. Choo, *Bioorg. Med. Chem.*, 2004, **12**, 3543–3552; b) D.-S. Su, M. K. Markowitz, R. M. DiPardo, K. L. Murphy, C. M. Harrell, S. S. O'Malley, R. W. Ransom, R. S. L. Chang, S. Ha, F. J. Hess, D. J. Pettibone, G. S. Mason, S. Boyce, R. M. Freidinger and M. G. Bock, *J. Am. Chem. Soc.*, 2003, **125**, 7516–7517.
 14. a) S. M. Bromidge, A. M. Brown, S. E. Clarke, K. Dodgson, T. Gager, H. L. Grassam, P. M. Jeffrey, G. F. Joiner, F. D. King, D. N. Middlemiss, S. F. Moss, H. Newman, G. Riley, C. Routledge and P. Wyman, *J. Med. Chem.*, 1999, **42**, 202–205; b) S. M. Bromidge, S. E. Clarke, T. Gager, K. Griffith, P. Jeffrey, A. J. Jennings, G. F. Joiner, F. D. King, P. J. Lovell, S. F. Moss, H. Newman, G. Riley, D. Rogers, C. Routledge, H. Serafinowska and D. R. Smith, *Bioorg. Med. Chem. Lett.*, 2001, **11**, 55–58; c) W. Kuipers, C. G. Kruse, I. van Wijngaarden, P. J. Standaar, M. T. M. Tulp, N. Veldman, A. L. Spek and A. P. Ijzerman, *J. Med. Chem.*, 1997, **40**, 300–312; d) M. Perez, C. Fourrier, I. Sigogneau, P. J. Pauwels, C. Palmier, G. W. John, J.-P. Valentin and S. Halazy, *J. Med. Chem.*, 1995, **38**, 3602–3607.
 15. S. Kitamura, H. Fukushi, T. Miyawaki, M. Kawamura, N. Konishi, Z.-i. Terashita and T. Naka, *J. Med. Chem.*, 2001, **44**, 2438–2450.
 16. a) M. Suzuki, M. Takashima-Hirano, H. Koyama, T. Yamaoka, K. Sumi, H. Nagata, H. Hidaka and H. Doi, *Tetrahedron*, 2012, **68**, 2336–2341; b) A. C. Valdivia, S. Mason, J. Collins, K. R. Buckley, P. Coletta, R. S. Beanlands and J. N. DaSilva, *Appl. Radiat. Isot.*, 2010, **68**, 325–328.
 17. a) M. M. Abelman, K. J. Fisher, E. M. Doerffler and P. J. Edwards, *Tetrahedron Lett.*, 2003, **44**, 1823–1826; b) D. C. Beshore and C. J.

- Dinsmore, *Org. Lett.*, 2002, **4**, 1201-1204; c) D. C. Horwell, R. A. Lewthwaite, M. C. Pritchard, G. S. Ratcliffe and J. Ronald Rubin, *Tetrahedron*, 1998, **54**, 4591-4606; d) J. N. Cumming, T. X. Le, S. Babu, C. Carroll, X. Chen, L. Favreau, P. Gaspari, T. Guo, D. W. Hobbs, Y. Huang, U. Iserloh, M. E. Kennedy, R. Kuvelkar, G. Li, J. Lowrie, N. A. McHugh, L. Ozgur, J. Pan, E. M. Parker, K. Saionz, A. W. Stamford, C. Strickland, D. Tadesse, J. Voigt, L. Wang, Y. Wu, L. Zhang and Q. Zhang, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 3236-3241; e) C. J. Dinsmore and C. B. Zartman, *Tetrahedron Lett.*, 2000, **41**, 6309-6312; f) R. C. Bernotas and G. Adams, *Tetrahedron Lett.*, 1996, **37**, 7339-7342; g) J. DiMaio and B. Belleau, *J. Chem. Soc., Perkin Trans. 1*, 1989, 1687-1689; h) S. Herrero, M. T. García-López, M. Latorre, E. Cenarruzabeitia, J. Del Río and R. Herranz, *J. Org. Chem.*, 2002, **67**, 3866-3873; i) P. Tošovská and P. S. Arora, *Org. Lett.*, 2010, **12**, 1588-1591; j) J. Gante, *Angew. Chem. Int. Edit.*, 1994, **33**, 1699-1720; k) A. Giannis and T. Kolter, *Angew. Chem. Int. Edit.*, 1993, **32**, 1244-1267; l) B. J. Min, X. Gu, T. Yamamoto, R. R. Petrov, H. Qu, Y. S. Lee and V. J. Hrubby, *Tetrahedron Lett.*, 2008, **49**, 2316-2319.
18. a) G. P. Pollini, N. Baricordi, S. Benetti, C. De Risi and V. Zanirato, *Tetrahedron Lett.*, 2005, **46**, 3699-3701; b) J.-H. Baek, J.-I. Jang and Y.-S. Park, *Bull. Korean Chem. Soc.*, 2011, **11**, 4067-4070.
19. Y. Kim, K. J. Park, M.-s. Lee, H. Ryu and Y. S. Park, *Bull. Korean Chem. Soc.*, 2014, **35**, 265-268.
20. S.-Y. Hsieh, M. Binanzer, I. Kreituss and J. W. Bode, *Chem. Commun.*, 2012, **48**, 8892-8894.
21. a) E. J. Corey and J. O. Link, *J. Am. Chem. Soc.*, 1992, **114**, 1906-1908; b) E. J. Corey and J. O. Link, *Tetrahedron Lett.*, 1992, **33**, 3431-3434; c) C. Domínguez, J. Ezquerro, S. Richard Baker, S. Borrelly, L. Prieto, M. Espada and C. Pedregal, *Tetrahedron Lett.*, 1998, **39**, 9305-9308; d) J. E. Oliver and W. F. Schmidt, *Tetrahedron: Asymmetry*, 1998, **9**, 1723-1728; e) A. Scaffidi, B. W. Skelton, R. V. Stick and A. H. White, *Aust. J. Chem.*, 2004, **57**, 723-732; f) A. Scaffidi, B. W. Skelton, R. V. Stick and A. H. White, *Aust. J. Chem.*, 2006, **59**, 426-433; g) J. L. Shamshina and T. S. Snowden, *Org. Lett.*, 2006, **8**, 5881-5884; h) L. R. Cafiero and T. S. Snowden, *Org. Lett.*, 2008, **10**, 3853-3856; i) A. Ganta, J. L. Shamshina, L. R. Cafiero and T. S. Snowden, *Tetrahedron*, 2012, **68**, 5396-5405; j) M. K. Gupta, Z. Li and T. S. Snowden, *J. Org. Chem.*, 2012, **77**, 4854-4860; k) T. S. Snowden, *ARKIVOK*, 2012, 24-40; l) J. R. Snider, J. T. Entrekin, T. S. Snowden and D. Dolliver, *Synthesis*, 2013, **45**, 1899-1903; m) M. K. Gupta, Z. Li and T. S. Snowden, *Org. Lett.*, 2014, **16**, 1602-1605.
22. a) J. S. M. Samec, J.-E. Backvall, P. G. Andersson and P. Brandt, *Chem. Soc. Rev.*, 2006, **35**, 237-248; b) A. Fujii, S. Hashiguchi, N. Uematsu, T. Ikariya and R. Noyori, *J. Am. Chem. Soc.*, 1996, **118**, 2521-2522; c) S. Hashiguchi, A. Fujii, J. Takehara, T. Ikariya and R. Noyori, *J. Am. Chem. Soc.*, 1995, **117**, 7562-7563; d) R. Noyori and S. Hashiguchi, *Acc. Chem. Res.*, 1997, **30**, 97-102; e) A. M. Hayes, D. J. Morris, G. J. Clarkson and M. Wills, *J. Am. Chem. Soc.*, 2005, **127**, 7318-7319; f) F. K. Cheung, A. J. Clarke, G. J. Clarkson, D. J. Fox, M. A. Graham, C. Lin, A. L. Criville and M. Wills, *Dalton Trans.*, 2010, **39**, 1395-1402.
23. Z. Jocić, *Zh. Russ. Fiz. Khim. Ova.*, 1897, **29**, 97-103.
24. M. S. Perryman, M. E. Harris, J. L. Foster, A. Joshi, G. J. Clarkson and D. J. Fox, *Chem. Commun.*, 2013, **49**, 10022-10024.
25. a) J. Katarzyńska, A. Mazur, E. Rudzińska, J. Artym, M. Zimecki, S. Jankowski and J. Zabrocki, *Eur. J. Med. Chem.*, 2011, **46**, 4608-4617; b) A. Y. Moreno, A. V. Mayorov and K. D. Janda, *J. Am. Chem. Soc.*, 2011, **133**, 6587-6595; c) S. Suwal and T. Kodadek, *Org. Biomol. Chem.*, 2013, **11**, 2088-2092.
26. J. T. Lai, *J. Org. Chem.*, 1980, **45**, 754-755.
27. J. T. Lai, *Synthesis*, 1981, **1981**, 40-42.
28. a) R. W. Hay and P. J. Morris, *J. Chem. Soc., Perkin Trans. 2*, 1972, 1021-1029; b) D. J. Fox, J. Reckless, S. M. Wilbert, I. Greig, S. Warren and D. J. Grainger, *J. Med. Chem.*, 2005, **48**, 867-874.
29. a) U. Bhatt, N. Mohamed, G. Just and E. Roberts, *Tetrahedron Lett.*, 1997, **38**, 3679-3682; b) I. Derdowska, A. Prah, B. Lammek, K. Neubert, B. Hartrodt, A. Kania, D. Dobrowolski, S. Malhem, H. I. Trzeciak and T. Wierzbak, *J. Peptide Res.*, 2001, **57**, 11-18; c) J. M. Kane and A. A. Carr, *Tetrahedron Lett.*, 1980, **21**, 3019-3020; d) B. H. Lee and M. F. Clothier, *Tetrahedron Lett.*, 1999, **40**, 643-644; e) C. L. Lencina, A. Dassonville-Klimpt and P. Sonnet, *Tetrahedron: Asymmetry*, 2008, **19**, 1689-1697; f) A. Pohlmann, V. Schanen, D. Guillaume, J.-C. Quirion and H.-P. Husson, *J. Org. Chem.*, 1997, **62**, 1016-1022; g) V. Schanen, M.-P. Cherrier, S. J. d. Melo, J.-C. Quirion and H.-P. Husson, *Synthesis*, 1996, **1996**, 833-837; h) T. Su, H. Yang, D. Volkots, J. Woolfrey, S. Dam, P. Wong, U. Sinha, R. M. Scarborough and B.-Y. Zhu, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 729-732; i) Y. Tong, Y. M. Fobian, M. Wu, N. D. Boyd and K. D. Moeller, *J. Org. Chem.*, 2000, **65**, 2484-2493.
30. a) K. E. Henegar, R. Lira, H. Kim and J. Gonzalez-Hernandez, *Org. Proc. Res. Dev.*, 2013, **17**, 985-990; b) C.-W. Lee, R. Lira, J. Dutra, K. Ogilvie, B. T. O'Neill, M. Brodney, C. Helal, J. Young, E. Lachapelle, S. Sakya and J. C. Murray, *J. Org. Chem.*, 2013, **78**, 2661-2669.